Docoh
Loading...

SYRS Syros Pharmaceuticals

News

From Benzinga Pro
12 Health Care Stocks Moving In Friday's Pre-Market Session
3 Dec 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
5 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Syros Pharmaceuticals Q3 EPS $(0.41) Beats $(0.44) Estimate, Sales $5.70M Beat $4.49M Estimate
5 Nov 21
Earnings, News
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.44) by 6.82 percent. This is a 4.65 percent increase over losses of $(0.43) per share
Earnings Scheduled For November 5, 2021
5 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter.
Earnings Preview For Syros Pharmaceuticals
4 Nov 21
Earnings
Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement. Analysts estimate that Syros Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-0.44
Syros Pharmaceuticals Names Jason Haas As CFO
12 Oct 21
News, Management
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25
Roth Capital Maintains Buy on Syros Pharmaceuticals, Raises Price Target to $23
23 Sep 21
News, Price Target, Analyst Ratings
Roth Capital analyst Zegbeh Jallah maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and raises the price target from $20 to $23.
12 Health Care Stocks Moving In Tuesday's Intraday Session
21 Sep 21
Intraday Update, Markets, Movers
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
20 Sep 21
News, Penny Stocks, Small Cap
Syros Pharma Highlights Presentation Of New Data From Phase 1 Trial Of SY-5609
20 Sep 21
Biotech, News, FDA, General
Updated Dose-Escalation Data Demonstrate Clinical Activity in Heavily Pre-treated Patients Across Multiple Tumor Types Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer
48 Biggest Movers From Friday
20 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
12 Health Care Stocks Moving In Friday's Intraday Session
17 Sep 21
Movers
Gainers
25 Stocks Moving In Friday's Mid-Day Session
17 Sep 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 92.7% to $17.35 after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
12 Health Care Stocks Moving In Friday's Pre-Market Session
17 Sep 21
Pre-Market Outlook, Markets, Movers
Syros Announces First Patient Dosed In SELECT-AML-1 Trial Of Tamibarotene In Combination With Venetoclax And Azacitidine In Newly Diagnosed Unfit AML
9 Sep 21
News, FDA
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of

Press releases

From Benzinga Pro
Syros to Participate in Upcoming Investor Conferences
16 Nov 21
Press Releases
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
5 Nov 21
Press Releases
First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Study of SY-2101 in APL Presented Phase 1 Data of SY-5609 at ESMO, Demonstrating Clinical Activity at Tolerable Doses and Supporting
Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021
29 Oct 21
Press Releases
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday,
Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)
13 Oct 21
Press Releases
Syros Pharmaceuticals (NASDAQ:SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option
Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
12 Oct 21
Press Releases
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25
Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
29 Sep 21
Press Releases
Confirmatory Dose and PK Data Expected in First Half of 2022, with a Phase 3 Trial Expected to Begin in 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of
Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
28 Sep 21
Press Releases
Syros Pharmaceuticals (NASDAQ:SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
20 Sep 21
Press Releases
Updated Dose-Escalation Data Demonstrate Clinical Activity in Heavily Pre-treated Patients Across Multiple Tumor Types Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
10 Sep 21
Press Releases
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company's Board of Directors. Dr.
Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
9 Sep 21
Press Releases
Initial Data from the Phase 2 Trial Expected in 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been